Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2001 Oct;92(10):1127–1132. doi: 10.1111/j.1349-7006.2001.tb01068.x

High Expression of Thymidylate Synthase Leads to Resistance to 5‐Fluorouracil in Biliary Tract Carcinoma in vitro

Kazuto Habara 1,✉, Tetsuo Ajiki 1,✉, Takashi Kamigaki 1,✉, Takeshi Nakamura 1,✉, Yoshikazu Kuroda 1,✉
PMCID: PMC5926613  PMID: 11676864

Abstract

To evaluate the effect of chemotherapy of 5‐fluorouracil (5‐FU) in human biliary tract carcinoma, we studied 5‐FU sensitivity, thymidylate synthase (TS) content, and dihydropyrimidine dehydroge‐nase (DPD) activity in 4 human biliary tract carcinoma cell lines compared to 12 various digestive carcinoma cell lines of human organs in vitro. 5‐FU sensitivity in the cell lines was analyzed by MTT assay. TS content was analyzed by the [6‐3H]FdUMP binding assay method, and DPD activity was analyzed by thin‐layer chromatography (TLC). 5‐FU lC50 values of biliary tract carcinoma cell lines were significantly higher than those of the carcinoma cell lines of the other digestive organs: 97, 45, 119, and 194 tunes the concentration of the other digestive, pancreas, colon, and gastric carcinoma cell lines, respectively. TS content of biliary tract carcinoma cell lines was also significantly greater than that of the carcinoma cell lines of the other organs. No difference in DPD activity, however, was recognized between the carcinoma cell lines of each organ. TS content in the cell lines significantly correlated with 5‐FU sensitivity, but DPD activity did not. Therefore, in the present study, TS expression was concluded to influence the high resistance to 5‐FU of biliary tract carcinoma in comparison with the carcinomas of the other digestive organs.

Keywords: Thymidylate synthase, Biliary tract carcinoma, 5‐Fluorouracil, Dihydropyrimidine dehydrogenase

Full Text

The Full Text of this article is available as a PDF (67.5 KB).

REFERENCES

  • 1. ) Moon , Y. , Dahlberg , W. K. , Yu , Y. , Ohno , T. , Todoroki , T. and Little , J. B.Radiosensitivity of human biliary tract cancer cell lines in vitro . Int. J. Oncol. , 10 , 545 – 551 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Harvey , J. H. , Smith , F. P. and Schein , P. S.5‐Fluorouracil, mitomycin, doxorubicin (FAM) in carcinoma of the biliary tract . J. Clin. Oncol. , 2 , 1245 – 1248 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Smith , G. W. , Bukowski , R. M. , Hewlett , J. S. and Groppe , C. W.Hepatic artery infusion of 5‐fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma . Cancer , 54 , 1513 – 1516 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Pitt , H. A. , Nakeeb , A. , Abrams , R. A. , Coleman , J. , Piantadosi , S. , Yeo , C. J. , Lillemoe , K. D. and Cameron , J. L.Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival . Ann. Surg. , 221 , 788 – 798 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. ) Heidelberger , C. , Chaudhuri , N. K. , Danneberg , P. , Mooren , D. , Griesbach , L. , Duschinsky , R. , Schnitzer , R. J. , Pleven , E. and Scheiner , J.Fluorinated pyrimidines, a new class of tumour‐inhibitory compounds . Nature , 179 , 663 – 666 ( 1957. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Diasio , R. B. and Harris , B. E.Clinical pharmacology of 5‐fluorouracil . Clin. Pharmacokinet. , 16 , 215 – 237 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Parker , W. B. and Cheng , Y. C.Metabolism and mechanism of action of 5‐fluorouracil . Pharmacol. Ther. , 48 , 381 – 395 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Weckbecker , G.Biochemical pharmacology and analysis of fluoropyrimidine alone and in combination with modulators . Pharmacol. Ther. , 50 , 367 – 424 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Berger , S. H. , Jehn , C. H. , Johnson , L. F. and Berger , F. G.Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine‐resistant human cells . Mol. Phamacol. , 28 , 461 – 467 ( 1985. ). [PubMed] [Google Scholar]
  • 10. ) Okabe , H. , Tsujimoto , H. and Fukushima , M.Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity‐study of 5‐fluorouracil . Oncol. Rep. , 4 , 685 – 690 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Peters , G. J. , Van der Wilt , C. L. , van Triest , B. , Codacci‐Pisanelli , G. , Johnston , P. G. , Van Groeningen , C. J. and Pinedo , H. M.Thymidylate synthase and drug resistance . Eur. J. Cancer , 31 , 1299 – 1305 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Heggie , G. D. , Sommadossi , J. P. , Cross , D. S. , Huster , W. J. and Diasio , R. B.Clinical pharmacokinetics of 5‐fluorouracil and its metabolites in plasma, urine, and bile . Cancer Res. , 47 , 2203 – 2206 ( 1987. ). [PubMed] [Google Scholar]
  • 13. ) Diasio , R. B. , Beavers , T. L. and Carpenter , J. T.Familial deficiency of dihydropyrimidine dehydrogenase; biochemical basis for familial pyrimidinemia and severe 5‐fluorouracilinduced toxicity . J. Clin. Invest. , 81 , 47 – 51 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. ) Harris , B. E. , Song , R. , Soong , S. J. and Diasio , R. B.Relationship between dihydropyrimidine dehydrogenase activity and plasma 5‐fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5‐fluorouracil by protracted continuous infusion . Cancer Res. , 50 , 197 – 201 ( 1990. ). [PubMed] [Google Scholar]
  • 15. ) Etienne , M. C. , Cheradame , S. , Fischel , J. L. , Formento , P. , Dassonville , O. , Renee , N. , Schneider , M. , Thyss , A. , Demard , F. and Milano , G.Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity . J. Clin. Oncol. , 13 , 1663 – 1670 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Beck , A. , Etienne , M. C. , Cheradame , S. , Fischel , J. L. , Formento , P. , Renee , N. and Milano , G.A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil . Eur. J. Cancer , 30 , 1517 – 1522 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Nita , M. E. , Tominaga , O. , Nagawa , H. , Tsuruo , T. and Muto , T.Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5‐fluorouracil in colorectal cancer . Hepatogastro-enterology , 45 , 2117 – 2122 ( 1998. ). [PubMed] [Google Scholar]
  • 18. ) Irinoda , T. , Terashima , M. , Kawamura , H. and Takagane , A.Prediction of 5‐fluorouracil sensibility by measurement of thymidylate synthase activity and dehydropyrimidine dehydrogenase activity against gastric cancer . Jpn. J. Gastroenterol. Surg. , 32 , 1955 – 1961 ( 1999. ). [Google Scholar]
  • 19. ) Lenz , H. J. , Leichman , C. G. , Danenberg , K. D. , Danenberg , P. V. , Groshen , S. , Cohen , H. , Laine , L. , Crookes , P. , Silberman , H. , Baranda , J. , Garcia , Y. , Li , J. and Leichman , L.Thymidylate synthase in mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival . J. Clin. Oncol. , 14 , 176 – 182 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Kuniyasu , T. , Nakamura , T. , Tabuchi , Y. and Kuroda , Y.Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody . Cancer , 83 , 1300 – 1306 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Yeh , K. H. , Shun , C. T. , Chen , C. L. , Lin , J. T. , Lee , W. J. , Lee , P. H. , Chen , Y. C. and Cheng , A. L.High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5‐fluorouracil‐based systemic chemotherapy . Cancer , 82 , 1626 – 1631 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Ishikawa , Y. , Kubota , T. , Otani , Y. , Watanabe , M. , Teramoto , T. , Kumai , K. , Takechi , T. , Okabe , H. , Fukushima , M. and Kitajima , M.Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5‐fluorouracil . Jpn. J. Cancer Res. , 91 , 105 – 112 ( 2000. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. ) Johnston , P. G. , Fisher , E. R. , Rockette , H. E. , Fisher , B. , Wolmark , N. , Drake , J. C. , Chabner , B. A. and Allegra , C. J.The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer . J. Clin. Oncol. , 12 , 2640 – 2647 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Kornmann , M. , Link , K. H. , Lenz , H. J. , Pillasch , J. , Metzger , R. , Butzer , U. , Leder , G. H. , Weindel , M. , Safi , F. , Danenberg , K. D. , Beger , H. G. and Danenberg , P. V.Thymidylate synthase is a predictor for response and resistance in hepatic infusion chemotherapy . Cancer Lett. , 118 , 29 – 35 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Lenz , H. J. , Hayashi , K. , Salonga , D. , Danenberg , K. D. , Danenberg , P. V. , Metzger , R. , Banerjee , D. , Bertino , J. R. , Groshen , S. , Leichman , L. P. and Leichman , C. G.p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival . Clin. Cancer Res. , 4 , 1243 – 1250 ( 1998. ). [PubMed] [Google Scholar]
  • 26. ) Yamachika , T. , Nakanishi , H. , Inada , K. , Tsukamoto , T. , Kato , T. , Fukushima , M. , Inoue , M. and Tatematsu , M.A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance . Cancer , 82 , 70 – 77 ( 1998. ). [PubMed] [Google Scholar]
  • 27. ) Salonga , D. , Danenberg , K. D. , Johnson , M. , Metzger , R. , Groshen , S. , Tsao Wei , D. D. , Lenz , H. J. , Leichman , C. G. , Leichman , L. , Diasio , R. B. and Danenberg , P. V.Colorectal tumors responding to 5‐fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase . Clin. Cancer Res. , 6 , 1322 – 1327 ( 2000. ). [PubMed] [Google Scholar]
  • 28. ) Knuth , A. , Gabbert , H. , Dippold , W. , Klein , O. , Sachsse , W. , Bitter‐Suermann , D. , Prellwitz , W. and Meyer zum Biischenfelde , K. H.Biliary adenocarcinoma characterisation of three new human tumor cell lines . J. Hepatol. , 1 , 579 – 596 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Homma , S. , Hasumura , S. , Nagamori , S. and Kameda , H.Establishment and characterization of a human gall bladder carcinoma cell line NOZ . Hum. Cell , 1 , 95 – 97 ( 1988. ). [PubMed] [Google Scholar]
  • 30. ) Mosmann , T.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays . J. Immunol. Methods , 65 , 55 – 63 ( 1983. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES